Galectin Therapeutics Inc. (GALT): Price and Financial Metrics


Galectin Therapeutics Inc. (GALT): $1.68

0.02 (+1.20%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GALT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

GALT Stock Price Chart Interactive Chart >

Price chart for GALT

GALT Price/Volume Stats

Current price $1.68 52-week high $3.78
Prev. close $1.66 52-week low $1.19
Day low $1.68 Volume 1,308
Day high $1.68 Avg. volume 95,360
50-day MA $1.92 Dividend yield N/A
200-day MA $1.77 Market Cap 99.79M

Galectin Therapeutics Inc. (GALT) Company Bio


Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company was founded in 2000 and is based in Norcross, Georgia.


GALT Latest News Stream


Event/Time News Detail
Loading, please wait...

GALT Latest Social Stream


Loading social stream, please wait...

View Full GALT Social Stream

Latest GALT News From Around the Web

Below are the latest news stories about GALECTIN THERAPEUTICS INC that investors may wish to consider to help them evaluate GALT as an investment opportunity.

Galectin Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference September 13, 2022

NORCROSS, Ga., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 24th Annual Global Investment Conference being held on September 12-14, 2022. The Wainwright Conference brings together thought leaders and practitioners from numerous fields to participate in presentations, one-on-one investor meetings, and networking opportunitie

Yahoo | September 8, 2022

Galectin Therapeutics (GALT) Gets a Buy from H.C. Wainwright

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Galectin Therapeutics (GALT - Research Report) today and set a price target of $11.00. The company's shares closed yesterday at $2.18.According to TipRanks, Arce is a 4-star analyst with an average return of 8.8% and a 40.31% success rate. Arce covers the Healthcare sector, focusing on stocks such as Assembly Biosciences, Pliant Therapeutics, and Galectin Therapeutics.Currently, the analyst consensus on Galectin Therapeutics is a Moderate Buy with an average price target of $11.00.See the top stocks recommended by analysts >>The company has a one-year high of $4.24 and a one-year low of $1.19.

Austin Angelo on TipRanks | August 16, 2022

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2022 and Provides Business Update

NORCROSS, Ga., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2022. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov. Joel Lewis, Chief Executive Officer and President, sta

Yahoo | August 15, 2022

Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024

NORCROSS, Ga., July 26, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today it entered into a $60 million unsecured line of credit facility with its chairman and largest individual stockholder, Richard E. Uihlein. “It has been close to fifteen years since I made my first investment in Galectin Therapeutics,” said Richard E. Uihlein, chairman of the board of directors. “While my role in the Company

Yahoo | July 26, 2022

Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations at the EASL International Liver Congress™ 2022

NORCROSS, Ga., June 21, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, announced today two scientific presentations regarding the use of artificial intelligence to analyze liver biopsies of patients affected with cirrhosis of the liver due to Nonalcoholic Steatohepatitis (NASH). The data originates from the Company’s phase 2 study (NCT02462967) that evaluated its proprietary drug candidate belapectin in patients w

Yahoo | June 21, 2022

Read More 'GALT' Stories Here

GALT Price Returns

1-mo -6.67%
3-mo 15.07%
6-mo 5.00%
1-year -54.47%
3-year -56.36%
5-year -30.86%
YTD -18.84%
2021 -7.59%
2020 -21.68%
2019 -16.62%
2018 2.69%
2017 240.82%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4972 seconds.